Multivariable Cox regression analysis for OS, RFS, and EFS
| . | OS HR (95% CI) . | P value . | RFS HR (95% CI) . | P value . | EFS HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Treatment group (ICH vs VenAza) | 1.82 (1.03-3.20) | .039 | 3.23 (1.04-10.08) | .043 | 1.72 (0.98-3.04) | .061 |
| Age (per year) | 1.02 (1.00-1.03) | .061 | 1.00 (0.97-1.02) | .761 | 1.01 (0.99-1.03) | .206 |
| Secondary AML (vs de novo) | 0.80 (0.36-1.78) | .584 | 1.48 (0.26-8.53) | .664 | 1.39 (0.70-2.78) | .347 |
| Risk (adverse vs nonadverse) | 1.39 (0.70-2.77) | .345 | 1.43 (0.54-3.79) | .474 | 1.19 (0.64-2.23) | .585 |
| Risk (unknown vs nonadverse) | 1.53 (0.87-2.71) | .143 | 1.27 (0.49-3.34) | .622 | 1.77 (1.07-2.91) | .025 |
| . | OS HR (95% CI) . | P value . | RFS HR (95% CI) . | P value . | EFS HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Treatment group (ICH vs VenAza) | 1.82 (1.03-3.20) | .039 | 3.23 (1.04-10.08) | .043 | 1.72 (0.98-3.04) | .061 |
| Age (per year) | 1.02 (1.00-1.03) | .061 | 1.00 (0.97-1.02) | .761 | 1.01 (0.99-1.03) | .206 |
| Secondary AML (vs de novo) | 0.80 (0.36-1.78) | .584 | 1.48 (0.26-8.53) | .664 | 1.39 (0.70-2.78) | .347 |
| Risk (adverse vs nonadverse) | 1.39 (0.70-2.77) | .345 | 1.43 (0.54-3.79) | .474 | 1.19 (0.64-2.23) | .585 |
| Risk (unknown vs nonadverse) | 1.53 (0.87-2.71) | .143 | 1.27 (0.49-3.34) | .622 | 1.77 (1.07-2.91) | .025 |
The treatment group remained independently associated with OS and RFS, while unknown-risk patients showed inferior EFS. Other baseline covariates were not significant. Bold values reflect P <.05.